Member Info for Richob

Looks like they are planning to take PNT2004 into the clinic this year. This is a FAPa trial, which they have licensed from Dr Bachovin and Avacta.

https://www.pointbiopharma.com/our-products/pipeline/solid-tumors

Onwards Avacta.

Tiffin, Timster?

How jolly decent of you.

Onwards Avacta.

The trial has been approved in the UK.

The trial has been approved in the US.

The safety committee (made up of the professional cancer treatment experts in charge of patient recruitment) has approved an increased dosage based on the data from the trial so far.

The trial is about delivering an existing cancer drug, so the drug itself is not on trial.

The market for cancer treatment is $230bn per annum.

It's not only us watching this with some interest.

This is global as neutronic said.

Onwards Avacta.

Interesting comment from the chap that runs Scale Space:

I see Scale Space having success in two ways. One is to create a new generation of scale-ups that are changing the world in their respective fields. The other is fundamentally reshaping our understanding of what it takes to create a successful scale-up that is grounded in research..

"Changing the world in their respective fields."

Well, AVA6000 is capable of changing the world of cancer treatment no doubt.

Onwards Avacta.

How on earth could I have forgotten the two million shares that have been added to the employee and director incentive schemes for achieving milestones?

Tut, Tut, must be slipping. Note to self.

Onwards Avacta.

Could it be the anticipated AVA6000 DE update?

Could it be another milestone with LG Chem?

Could it be a milestone payment with Daewoong?

Could it be Affyxell going into a clinical trial?

Could it be Point Biopharma moving forwards with a radio ligand?

I'm sure Energyshares could add to that list.

Onwards Avacta.

And the "Os".

More bought than sold this morning, Timster.

No shenanigans, of course.

Onwards Avacta.

Completely agree, LLnP,

The timing of the incentive scheme block shares says a lot to me given that the company will know what the AVA6000 data looks like.

Pointless allocating shares to incentive schemes if there is no incentive to buy them at the incentive price. A big clue I reckon.

I am not usually an RNS predictor but would be surprised if there is no RNS in the next week or so.

Onwards Avacta.

Timster,

Can you imagine the impact if the AVA6000 approach is, say, twice as good, five times as good?

Eighteen times better would blow the doors off cancer treatment going forward.

I obviously believe they have cracked this.

Onwards Avacta.

Bonus time for the patients.

Onwards Avacta.

Don't think the 1:18 matters at this point, Timster.

According to the Clinical Trial criteria "This open-label, First-into-Human (FIH) study will evaluate the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000, a FAP-activated pro-drug of doxorubicin, in patients with locally advanced and/or metastatic solid tumours. In Phase Ia, using a 3+3 design, escalating doses of AVA6000 will be administered to patients with a range of solid tumour types to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). In Phase 1b, the selected RP2D dose will be assessed in one to three tumour types."

I have taken that to mean that safety and tolerability are key initially and The Safety Committee have agreed that they have been, so we move forward. It works (so far then) it would seem.

Onwards Avacta.

Which sites come on and when is probably more dependent on their specialist cancer unit.

For example, Sheffield and Newcastle, not yet recruiting In the UK, are lung cancer and melanoma.

Not sure that the phase is that relevant.

Onwards Avacta.

And why do they need them there for "around the 9th of May"?

Onwards Avacta.

Bella,

These shares aren't for sale to Joe Public.

They are part of the company's incentive schemes where employees are given options for achieving key milestones.

The company needs them there to be able to offer the options as key milestones are achieved by employees.

I think this us very positive timing wise with what we know is happening.

Onwards Avacta.

I like it too, gmcc.

Also like this from Avacta's website:

https://avacta.com/therapeutics/precision/

A pretty good explanation of why this will work I thought.

Onwards Avacta.

Spot on, Mr Ripley.

Onwards Avacta.

...we went blue.

Onwards Avacta.

Hiya, Timster,

Just seen your post.

Interestingly, Point don't disclose Canseek targets. Im sure they have their reasons and will undoubtedly be watching AVA6000 with great interest, as are we.

Another iron in the fire.

Onwards Avacta.

Seem quite excited about Canseek:

https://www.pointbiopharma.com/our-products/pipeline/canseek

Amazing how others are now picking up on effects outside of the targetted tumour and a good advert for PrecIsion.

Onwards Avacta.